Poly(ADP-ribose)polymerase 1 (PARP-1) activation and Ca2+ permeable α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) channels in post-ischemic brain damage: New therapeutic opportunities?

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 5, 2015, Pages 636-646

  Gerace, Elisabetta ^a   Pellegrini Giampietro, Domenico E ^a   Moroni, Flavio ^b   Mannaioni, Guido ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Cell death; Dementia; Neuroprotection; Poly(ADP ribose) polymerases; Stroke; amino 3 hydroxy 5 methyl 4 isoxazolepropionic acid (AMPA) receptors

Indexed keywords

1 NAPHTHYL ACETYL SPERMINE; 2,3 DIHYDROXY 6 NITRO 7 SULFAMOYL BENZO[F]QUINOXALINE 2,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; AMPA RECEPTOR ANTAGONIST; APOPTOSIS INDUCING FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; GLUTAMATE RECEPTOR 2; HISTONE H1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; METHYLNITRONITROSOGUANIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN BNIP3; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; UNCLASSIFIED DRUG; CALCIUM; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PARP1 PROTEIN, RAT;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COGNITIVE DEFECT; DNA DAMAGE; ENZYME ACTIVATION; GLIA; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HUMAN; LONG TERM POTENTIATION; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVE CELL NECROSIS; NERVE CELL PLASTICITY; NERVE DEGENERATION; PYRAMIDAL NERVE CELL; ANIMAL; BIOLOGICAL MODEL; BRAIN INJURIES; COMPLICATION; DRUG EFFECTS; METABOLISM; RAT;

ANIMALS; BRAIN INJURIES; BRAIN ISCHEMIA; CALCIUM; ENZYME ACTIVATION; HUMANS; METHYLNITRONITROSOGUANIDINE; MODELS, BIOLOGICAL; POLY(ADP-RIBOSE) POLYMERASES; RATS; RECEPTORS, AMPA;

EID: 84930513417     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150430162841     Document Type: Article

References (101)

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612-23.
2. Tymianski M. Novel approaches to neuroprotection trials in acute ischemic stroke. Stroke 2013; 44: 2942-50.
3. Tymianski M. Stroke in 2013: disappointments and advances in acute stroke intervention. Nat Rev Neurol 2014; 10: 66-8.
4. Moskowitz MA. Brain protection: maybe yes, maybe no. Stroke 2010; 41: S85-6.
5. Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-50.
6. Moroni F. Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage. Curr Opin Pharmacol 2008; 8: 96-103.
7. Benveniste H, Drejer J, Schousboe A, Diemer N. Elevation of extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem 1984; 43: 1369-74.
8. Lombardi G, Moroni F, Jr., Moroni F. Glutamate receptor antagonists protect against ischemia-induced retinal damage. Eur J Pharmacol 1994; 271: 489-95.
9. Lombardi G, Moroni F. GM1 ganglioside reduces ischemiainduced excitatory amino acid output: a microdialysis study in the gerbil hippocampus. Neurosci Lett 1992; 134: 171-4.
10. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988; 1: 623-34.
11. Lipton SA. Rosenberg PA. Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994; 330: 613-22.
12. Meldrum B. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci 1985; 68: 113-22.
13. Schwarcz R, Meldrum B. Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders. Lancet 1985; 2: 140-3.
14. Moroni F, Lombardi G, Thomsen C, et al. Pharmacological characterization of 1-aminoindan-1,5-dicarboxylic acid (AIDA), a potent mGluR1 antagonist. J Pharmacol Exp Ther 1997; 281: 721-9.
15. Pellegrini-Giampietro DE, Peruginelli F, Meli E, et al. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: time course and mechanisms. Neuropharmacology 1999; 38: 1607-21.
16. Moroni F, Chiarugi A. Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J 2009; 276: 36-45.
17. Hamby AM, Suh SW, Kauppinen TM, Swanson RA. Use of a poly(ADP-ribose) polymerase inhibitor to suppress inflammation and neuronal death after cerebral ischemia-reperfusion. Stroke 2007; 38: 632-6.
18. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005; 4: 421-40.
19. Koh SH, Chang DI, Kim HT, et al. Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model. Toxicology 2005; 214: 131-9.
20. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med 2014; 2: 80.
21. Gerace E, Masi A, Resta F, et al. PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca(2+)-permeable AMPA receptors. Neurobiol Dis 2014; 70: 43-52.
22. Moroni F, Cozzi A, Chiarugi A, et al. Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable poly(ADP-ribose) polymerase inhibitors. Br J Pharmacol 2012; 165: 1487-500.
23. de Murcia G, Menisser-de Murcia J, Schreiber V. Poly(ADPribose) polymerase: a molecular nick sensor. Trends Biochem Sci 1992; 19: 172-6.
24. Kraus WL, Hottiger MO. PARP-1 and gene regulation: progress and puzzles. Mol Aspects Med 2013; 34: 1109-23.
25. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 882-93.
26. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA. Ischemic brain injury is mediated by the activation of poly(ADPribose) polimerase. J Cereb Blood Flow Metab 1997; 17: 1143-51.
27. Szabo C, Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998; 19: 287-98.
28. Cosi C, Suzuki H, Milani D, et al. Poly(ADP-ribose)polymerase: early involvement in glutamate-induced neurotoxicity in cultured cerebellar granule cells. J Neurosci Res 1994; 39: 38-46.
29. Zhang J, Dawson VL, Dawson TM, Snyder SH. Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity. Science 1994; 263: 687-9.
30. Berger NA. Poly(ADP-ribose) in the cellular response to DNA damage. Radiat Res 1985; 101: 4-15.
31. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol Dis 2000; 7: 225-39.
32. Pieper A, Verma A, Zhang J, Snyder SH. Poly(ADPribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 1999; 20: 171-81.
33. Goto S, Xue R, Sugo N, et al. Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery. Stroke 2002; 33: 1101-6.
34. Cozzi A, Cipriani G, Fossati S, et al. Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice. J Cereb Blood Flow Metab 2006; 26: 684-95.
35. Giovannelli L, Cozzi A, Guarnieri I, Dolara P, Moroni F. Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors. J Cereb Blood Flow Metab 2002; 22: 697-704.
36. Ying W, Alano CC, Garnier P, Swanson RA. NAD+ as a metabolic link between DNA damage and cell death. J Neurosci Res 2005; 79: 216-23.
37. Ying W, Chen Y, Alano CC, Swanson RA. Tricarboxylic acid cycle substrates prevent PARP-mediated death of neurons and astrocytes. J Cereb Blood Flow Metab 2002; 22: 774-9.
38. Endres M, Wang ZQ, Namura S, Waeber C, Moskowitz MA. Ischemic brain injury is mediated by the activation of poly(ADPribose) polymerase. J Cereb Blood Flow Metab 1997; 17: 1143-51.
39. Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 2014; 171: 2000-16.
40. Wang Y, Kim NS, Haince JF, et al. Poly(ADP-ribose) (PAR) binding to apoptosis-inducing factor is critical for PAR polymerase-1-dependent cell death (parthanatos). Sci Signal 2011; 4: ra20.
41. Culmsee C, Zhu C, Landshamer S, et al. Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci 2005; 25: 10262-72.
42. Fonfria E, Marshall IC, Benham CD, et al. TRPM2 channel opening in response to oxidative stress is dependent on activation of poly(ADP-ribose) polymerase. Br J Pharmacol 2004; 143: 186-92.
43. Yu SW, Andrabi SA, Wang H, et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006; 103: 18314-9.
44. Zhang Y, Zhang X, Park TS, Gidday JM. Cerebral endothelial cell apoptosis after ischemia-reperfusion: role of PARP activation and AIF translocation. J Cereb Blood Flow Metab 2005; 25: 868-77.
45. Lenzser G, Kis B, Snipes JA, et al. Contribution of poly(ADPribose) polymerase to postischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 2007; 27: 1318-26.
46. Orsini F, Villa P, Parrella S, et al. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 2012; 126: 1484-94.
47. Jorgensen MB, Finsen BR, Jensen MB, Castellano B, Diemer NH, Zimmer J. Microglial and astroglial reactions to ischemic and kainic acid-induced lesions of the adult rat hippocampus. Exp Neurol 1993; 120: 70-88.
48. Fumagalli S, Perego C, Ortolano F, De Simoni MG. CX3CR1 deficiency induces an early protective inflammatory environment in ischemic mice. Glia 2013; 61: 827-42.
49. Iadecola C. Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14: 89-94.
50. del Zoppo GJ. Stroke and neurovascular protection. N Engl J Med 2006; 354: 553-5.
51. del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab 2003; 23: 879-94.
52. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci USA 1998; 95: 15769-74.
53. Lampl Y, Boaz M, Gilad R, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404-10.
54. Alano CC, Kauppinen TM, Valls AV, Swanson RA. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci USA 2006; 103: 9685-90.
55. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006; 7: 517-28.
56. Kraus WL, Lis JT. PARP goes transcription. Cell 2003; 113: 677-83.
57. Langelier MF, Ruhl DD, Planck JL, Kraus WL, Pascal JM. The Zn3 domain of human poly(ADP-ribose) polymerase-1 (PARP-1) functions in both DNA-dependent poly(ADP-ribose) synthesis activity and chromatin compaction. J Biol Chem 2010; 285: 18877-87.
58. Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, Kininis M, Kraus WL. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 2008; 319: 819-21.
59. Szabo C, Dawson VL. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol Sci 1998; 19: 287-98.
60. Zingarelli B, Salzman AL, Szabo C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998; 83: 85-94.
61. Otsuka A, Hanafusa T, Miyagawa J, Kono N, Tarui S. Nicotinamide and 3-aminobenzamide reduce interferon-gammainduced class II MHC (HLA-DR and-DP) molecule expression on cultured human endothelial cells and fibroblasts. Immunopharmacol Immunotoxicol 1991; 13: 263-80.
62. Chiarugi A, Moskowitz MA. Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders. J Neurochem 2003; 85: 306-17.
63. Haddad M, Rhinn H, Bloquel C, et al. Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice. Br J Pharmacol 2006; 149: 23-30.
64. Koh SH, Park Y, Song CW, et al. The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals. Eur J Neurosci 2004; 20: 1461-72.
65. Bhakar AL, Tannis LL, Zeindler C, et al. Constitutive nuclear factor-kappa B activity is required for central neuron survival. J Neurosci 2002; 22: 8466-75.
66. Lu P, Kamboj A, Gibson SB, Anderson CM. Poly(ADP-Ribose) Polymerase-1 Causes Mitochondrial Damage and Neuron Death Mediated by Bnip3. J Neurosci 2014; 34: 15975-87.
67. Traynelis SF, Wollmuth LP, McBain CJ, et al. Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010; 62: 405-96.
68. Hollmann M, Hartley M, Heinemann S. Ca2+ permeability of KAAMPA-gated glutamate receptor channels depends on subunit composition. Science 1991; 252: 851-3.
69. Verdoorn TA, Burnashev N, Monyer H, Seeburg PH, Sakmann B. Structural determinants of ion flow through recombinant glutamate receptor channels. Science 1991; 252: 1715-8.
70. Burnashev N, Monyer H, Seeburg PH, Sakmann B. Divalent ion permeability of AMPA receptor channels is dominated by the edited form of a single subunit. Neuron 1992; 8: 189-98.
71. Sommer B, Köhler M, Sprengel R, Seeburg PH. RNA editing in brain controls a determinant of ion flow in glutamate-gated channels. Cell 1991; 67: 11-9.
72. Bochet P, Audinat E, Lambolez B, et al. Subunit composition at the single-cell level explains functional properties of a glutamate-gated channel. Neuron 1994; 12: 383-8.
73. Pellegrini-Giampietro DE, Gorter JA, Bennett MV, Zukin RS. The GluR2 (GluR-B) hypothesis: Ca(2+)-permeable AMPA receptors in neurological disorders. Trends Neurosci 1997; 20: 464-70.
74. Liu SJ, Zukin RS. Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci 2007; 30: 126-34.
75. Noh KM, Yokota H, Mashiko T, Castillo PE, Zukin RS, Bennett MV. Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc Natl Acad Sci USA 2005; 102: 12230-5.
76. Gu JG, Albuquerque C, Lee CJ, MacDermott AB. Synaptic strengthening through activation of Ca2+-permeable AMPA receptors. Nature 1996; 381: 793-6.
77. Scobie KN, Damez-Werno D, Sun H, et al. Essential role of poly(ADP-ribosyl)ation in cocaine action. Proc Natl Acad Sci USA 2014; 111: 2005-10.
78. Bellone C, Luscher C. Cocaine triggered AMPA receptor redistribution is reversed in vivo by mGluR-dependent long-term depression. Nat Neurosci 2006; 9: 636-41.
79. Mameli M, Halbout B, Creton C, et al. Cocaine-evoked synaptic plasticity: persistence in the VTA triggers adaptations in the NAc. Nat Neurosci 2009; 12: 1036-41.
80. Pellegrini-Giampietro DE, Zukin RS, Bennett MVL, Cho S, Pulsinelli WA. Switch in glutamate receptor subunit gene expression in CA1 subfield of hippocampus following global ischemia in rats. Proc Natl Acad Sci USA 1992; 89: 10499-503.
81. Pollard H, Héron A, Moreau J, Ben-Ari Y, Khrestchatisky M. Alterations of the GluR-B AMPA receptor subunit flip/flop expression in kainate-induced epilepsy and ischemia. Neuroscience 1993; 57: 545-54.
82. Heurteaux C, Lauritzen I, Widmann C, Lazdunski M. Glutamateinduced overexpression of NMDA receptor messenger RNAs and protein triggered by activation of AMPA/kainate receptors in rat hippocampus following forebrain ischemia. Brain Res 1994; 659: 67-74.
83. Tsubokawa H, Oguro K, Masuzawa T, Kawai N. Ca2+-dependent non-NMDA receptor-mediated synaptic currents in ischemic CA1 hippocampal neurons. J Neurophysiol 1994; 71: 1190-6.
84. Oguro K, Oguro N, Kojima T, et al. Knockdown of AMPA receptor GluR2 expression causes delayed neurodegeneration and increases damage by sublethal ischemia in hippocampal CA1 and CA3 neurons. J Neurosci 1999; 19: 9218-27.
85. Liu S, Lau L, Wei J, et al. Expression of Ca(2+)-permeable AMPA receptor channels primes cell death in transient forebrain ischemia. Neuron 2004; 43: 43-55.
86. Friedman LK, Pellegrini-Giampietro DE, Sperber EF, Bennett MVL, Moshé SL, Zukin RS. Kainate-induced status epilepticus alters glutamate and GABAA receptor gene expression in adult rat hippocampus: an in situ hybridization study. J Neurosci 1994; 14: 2697-707.
87. Grooms SY, Opitz T, Bennett MV, Zukin RS. Status epilepticus decreases glutamate receptor 2 mRNA and protein expression in hippocampal pyramidal cells before neuronal death. Proc Natl Acad Sci USA 2000; 97: 3631-6.
88. Brusa R, Zimmermann F, Koh DS, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science 1995; 270: 1677-80.
89. Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, Harrison PJ. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 1995; 29: 211-23.
90. Virgo L, Samarasinghe S, de Belleroche J. Analysis of AMPA receptor subunit mRNA expression in control and ALS spinal cord. NeuroReport 1996; 7: 2507-11.
91. Ikonomovic MD, Mizukami K, Davies P, Hamilton R, Sheffield R, Armstrong DM. The loss of GluR2(3) immunoreactivity precedes neurofibrillary tangle formation in the entorhinal cortex and hippocampus of Alzheimer brains. J Neuropathol Exp Neurol 1997; 56: 1018-27.
92. Gerace E, Scartabelli T, Formentini L, et al. Mild activation of poly(ADP-ribose) polymerase (PARP) is neuroprotective in rat hippocampal slice models of ischemic tolerance. Eur J Neurosci 2012; 36: 1993-2005.
93. Meli E, Pangallo M, Picca R, Baronti R, Moroni F, Pellegrini-Giampietro DE. Differential role of poly(ADP-ribose) polymerase-1in apoptotic and necrotic neuronal death induced by mild or intense NMDA exposure in vitro. Mol Cell Neurosci 2004; 25: 172-80.
94. Pellegrini-Giampietro DE, Cozzi A, Peruginelli F, et al. 1-Aminoindane-1,5dicarbossilic acid and (s)-(+)-2-(3'-carboxybiciclo[1.1.1]pentyl)-glycine, two mGlu 1 receptorpreferring antagonists, reduce neuronal death in in vitro and in vivo models of cerebral ischemia. Eur J Neurosci 1999; 11: 3637-47.
95. Scartabelli T, Gerace E, Landucci E, Moroni F, Pellegrini-Giampietro DE. Neuroprotection by group I mGlu receptors in a rat hippocampal slice model of cerebral ischemia is associated with the PI3K-Akt signaling pathway: a novel postconditioning strategy? Neuropharmacology 2008; 55: 509-16.
96. Pellegrini-Giampietro DE, Cozzi A, Moroni F. The glycine antagonist and free radical scavenger 7-Cl-thio-kynurenate reduces CA1 ischemic damage in the gerbil. Neuroscience 1994; 63: 701-9.
97. Moroni F, Formentini L, Gerace E, et al. Selective PARP-2 inhibitors increase apoptosis in hippocampal slices but protect cortical cells in models of post-ischaemic brain damage. Br J Pharmacol 2009; 157: 854-62.
98. Fatokun AA, Liu JO, Dawson VL, Dawson TM. Identification through high-throughput screening of 4'-methoxyflavone and 3',4'-dimethoxyflavone as novel neuroprotective inhibitors of parthanatos. Br J Pharmacol 2013; 169: 1263-78.
99. Lee Y, Karuppagounder SS, Shin JH, et al. Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci 2013; 16: 1392-400.
100. 00] Cipriani G, Rapizzi E, Vannacci A, Rizzuto R, Moroni F, Chiarugi A. Nuclear poly(ADP-ribose) polymerase-1 rapidly triggers mitochondrial dysfunction. J Biol Chem 2005; 280: 17227-34.
101. 01] Weiss JH. Ca permeable AMPA channels in diseases of the nervous system. Front Mol Neurosci 2011; 4: 42.